A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
- Conditions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2008-03-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00059735
Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy
- Conditions
- First Posted Date
- 2003-03-19
- Last Posted Date
- 2011-07-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT00056576
- Locations
- πΊπΈ
Suncoast Neuroscience Associates, Inc., St. Petersburg, Florida, United States
πΊπΈAMO Corporation, Tallahassee, Florida, United States
πΊπΈFlorida Epilepsy & Seizure Disorder Center, PA, Tampa, Florida, United States
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
- Conditions
- First Posted Date
- 2003-02-21
- Last Posted Date
- 2009-04-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT00055146
- Locations
- π¦π·
Montecaseros, Mendoza, Argentina
π¨π¦Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada
π¦πΊPeter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 623
- Registration Number
- NCT00050973
- Locations
- π¬π§
Guys & St. Thomas' Cancer Centre, London, England, United Kingdom
π¨π¦Cancer Care Manitoba, Winnepeg, Manitoba, Canada
πΊπΈUniversity Oncology & Hematology Associates, Chattanooga, Tennessee, United States
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT00050960
- Locations
- πΊπΈ
Pacific Coast Hematology/Oncology Medical Group, Inc., Fountain Valley, California, United States
πΊπΈUCLA Medical Center, Los Angeles, California, United States
πΊπΈCancer Institute of Long Island, Inc., Great Neck, New York, United States
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
- Conditions
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2008-03-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT00051012
- Locations
- π΅π±
Regional Oncological Center, Dept. of Chemotherapy, Lodz, Poland
π©πͺUniversitatsklinikum Charite, Berlin, Germany
π¦πΊLevel 4 Department of Haematology Royal North Shore Hospital, St. Leonard's, New South Wales, Australia
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
- Conditions
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2008-03-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT00050999
- Locations
- π¦πΉ
Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria
π΅π±Medical Academy in Gdansk, Dept. of Hematology, Gdansk, Poland
π΅π±Klinika Hematoonkologii Akademii Medycznej w Lublinie, Lublin, Poland
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
- Conditions
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00051025
- Locations
- πΊπΈ
Hematology and Oncology Services, Metairie, Louisiana, United States
πΊπΈCentral Baptist Hospital, Lexington, Kentucky, United States
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
- Conditions
- First Posted Date
- 2002-09-20
- Last Posted Date
- 2005-12-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00046072